|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,185 JPY | +0.68% |
|
+1.57% | -2.94% |
| Apr. 10 | Japan's Nikkei slips on caution ahead of US inflation data | RE |
| Mar. 29 | Chugai Pharmaceutical to Allocate 594 Million Yen of Treasury Shares as Restricted Stock Compensation | MT |
The ALEX study compared Alecensa and crizotinib as the first-line therapy for patients with ALK fusion gene positive non-small cell lung cancer (NSCLC).
Contact:
Tel: +81-3-3273-0881
Email: pr@chugai-pharm.co.jp
(C) 2020 Electronic News Publishing, source
| 1st Jan change | Capi. | |
|---|---|---|
| -2.94% | 54.75B | |
| +27.92% | 659B | |
| +27.68% | 557B | |
| -4.59% | 359B | |
| +16.38% | 322B | |
| +9.39% | 297B | |
| +6.30% | 215B | |
| +4.80% | 210B | |
| -6.05% | 200B | |
| -8.58% | 149B |
CHUGAI PHARMACEUTICAL CO., LTD 
